The first insulin, the original aspirational eye drop ... They want to build the world's most advanced treatment plan

When it comes to the predecessor of Wuhan Pharmaceutical Factory of Yuanda Pharmaceutical, many people are not unfamiliar. It is one of the "eight major pharmaceutical factories" of New China chemical pharmaceuticals, and can be traced back to the Eighth Route Army's sanitary material factory. Yuanda Pharmaceutical successfully developed China's first Chaihu injection, the first insulin, and the original closure of the internal eye drop. my country's first anti -platelet injection drugs -hydrochloric acid for Luo Feiban is also born. With a glorious past medicine, there are unusual pressure at the moment.

"We work day after day, to build the world's most advanced treatment plan for Chinese doctors and patients, innovate to the extreme, and medical treatment!" On June 24th, Dr. Tang Weikun, the chairman of the board of directors of Yuanda Pharmaceutical Group, President of Yuanda Pharmaceutical (China) Co., Ltd. Be a guest Hubei Daily 5G studio, share the story of Yuanda Medicine, and keep moving towards the peak of pharmaceutical research.

Business card

Yuanda Pharmaceutical (China) Co., Ltd. is a science and technology innovation -oriented international pharmaceutical enterprise integrating pharmaceutical, nuclear medicine and cardiovascular and cerebrovascular intervention diagnosis and treatment, synthetic biological industry (amino acid series, etc.). Enterprise was formerly a sanitary material factory established in the Eighth Route Army's Taihang Mountain Revolutionary Base in 1939. In 2008, Yuanda Pharmaceutical became the core member of the Hong Kong listed company, the Yuanda Pharmaceutical Group (stock code: 00512.HK). At present, Yuanda Pharmaceutical has more than 30 member companies, focusing on tumor diagnosis and treatment, cardiovascular and cerebrovascular first aid preparations, high -end cardiovascular and cerebrovascular intervention medical devices, severe and anti -infection, breathing and five officials, and synthetic biological products and boutique materials medicine. Multiple business areas.

In recent years, Yuanda Pharmaceutical has adhered to the development concept of "comprehensive advantages, innovation leadership and global expansion", and has established in -depth cooperative relationships with the world's leading pharmaceutical companies, overseas high -tech companies, universities and scientific research institutions, and has a forward -looking layout global innovation and a look. In advanced fields, five technology research and development platforms and 5 R & D centers have been established worldwide to coordinate the promotion of international innovation layout.

01

Introduce liver cancer innovation medicine regardless of cost

On June 19, the only product in the world's only product for colorectal cancer liver metastasis 钇 [90Y] microsphere injection was listed in China. This is a global innovation product introduced by the Yuanda Pharmaceutical United in China in 2018 to invest nearly 10 billion yuan from Australia Medical Device Company SiRTEX.

It is reported that 钇 [90Y] is used in more than 50 countries and regions around the world, with more than 150,000 patients, and is recommended by multiple international authoritative institutions into the clinical practice guide. But before the official introduction, this medicine was not applied in China.

"The pain of liver cancer patients has always led to our sight." Tang Weikun said that this is why enterprises have invested huge resources to allow this innovative drug to serve Chinese patients.

Liver cancer is called the "king of cancer". In February 2022, the National Cancer Center released the latest national cancer statistics data showed that China ’s new liver cancer annually reached 400,000 cases, accounting for about 47.6% of the new cases of liver cancer. Essence Most patients are already in the middle and late stages. Only 20%to 30%of patients with liver cancer can be treated through surgical resection, and the recurrence rate is still as high as 60%to 70%within 5 years. "Therefore, we urgently need an effective drug for the treatment of liver cancer." Tang Weikun admitted.

In September 2021, Dong Jiahong, an academician of the Chinese Academy of Engineering and the dean of Beijing Tsinghua Changgeng Hospital, Tsinghua University, led the multidisciplinary medical team of Beijing Tsinghua Chang Gung Hospital to implement the first franchise 钇 [90Y] microsphere injection in Hainan Province-90 Resin microspheres treat liver cancer surgery. After treatment, the tumor continues to shrink, and the venous tumor thrombus completely subsides. In March of this year, the patient underwent liver tumor resection at Chang Geng Hospital in Beijing and obtained the final cure of advanced liver cancer. "钇 [90Y] Micro ball injection can be able to kill liver tumor cells in the blood vessels inside the tumor by releaseing pure β -rays, push tumors to enable tumor cells Excited. "Tang Weikun revealed. On January 30 this year, 9 [90Y] Micro ball injection solution was approved by the State Drug Administration. Since February, the three hospitals in Tianjin, Shaanxi, Jiangsu, Hangzhou, Hunan, Liaoning, and Haikou have successfully implemented a number of patients with accurate intervention surgery for many patients.

"To meet the unsatisfactory clinical needs as the starting point, the product layout. This is the belief that Yuanda Medicine upholds." Tang Weikun said.

02

Not only can it be used, but also affordable

A high -priced medicine will inevitably cause patients to be greatly reduced. From the perspective of Yuanda Medicine, medicines must not only make patients use it, but also afford it.

When introducing 9 [90Y] microsphere injection, Yuanda Medicine began another plan. Tang Weikun revealed that Hubei is an important strategic place for the layout of the nuclear pharmaceutical nuclear medicine. The company is planning the construction of the production and development platform of the [90Y] microsphere injection product production and development platform, strengthen the development of new drug research and development, related radioactive drugs and pharmaceutical technology, and the development of high -end pharmaceutical medical device manufacturing. Its deeper meaning is that these drugs that have exact but expensive effects have been stepped up to reduce "worth" and serve more Chinese patients.

Tang Weikun admits that in terms of product research and development, the cycle of new drugs and high risks, the cost and risk capacity of the Chinese market are relatively weak. To this end, the company has adopted the idea of ​​global R & D layout. Global R & D centers carried out their own research and development; on the other hand, relying on the business expansion department to find the most suitable and leading technology to carry out localization in the world. Today, Yuanda Pharmaceutical has developed into a group company with more than 30 member companies in the world. By adopting independent research and development and global expansion of double -wheel drive, Yuanda Pharmaceutical has formed a new pattern of dual -cycle linkage development at home and abroad and promoting each other.

Through integration, Yuanda Pharmaceutical has achieved product introduction and domesticization. A number of global innovative products such as purulent poison and sub -fluids are used in the clinic. The price benefits a large number of patients. In 2021, the enterprise completed a total of 8 products introduced, of which 4 high -end medical equipment, 2 tumor fields, 1 ophthalmic field, and 1 in severe condition.

"In the process of development and growth, more outstanding enterprises and talents have joined in. From generation to generations, adults have cast DNAs that have done things, cure diseases, and do not forget their original intentions. This is also the inexhaustible development of our company's long -term healthy development Power. "Tang Weikun said with emotion. From the "life -saving medicine" two -cymbal propylene glycol for more than 60 years of production and treatment of heavy metal poisoning to insisting on the production of 6 national small varieties shortage medicines. In Tang Weikun's view, pharmaceutical companies are not only pursuing profits, but also a conscience and responsibility. For some patients' longing, even if they are money, they should meet the needs of the market.

03

Three important areas continue to make efforts

Tang Weikun knows that innovation is an inexhaustible motivation for a pharmaceutical company to continue to develop.

Since 2015, with the deepening of the concept of innovation and development and the improvement of international layout capabilities, Big Medicine has gradually established the three areas of accurate intervention, anti -tumor, intensive and anti -infection with the sense of smell. Investment portfolio and business partner circle of domestic and foreign companies.

In terms of technology, the innovation results achieved by Yuanda Medicine are also remarkable. In the field of precise intervention, 10 global innovation products have been reserved, covering six directions: coronary vascular intervention, peripheral vascular intervention, neurological intervention, structural heart disease, electrical physiology, and heart failure. Product RESTORE and APERTO have been successfully listed. In addition, Yuanda Medicine has also established overseas R & D platforms and production bases in North America and Europe, which continues to develop innovative products. In Changzhou and Wuhan Optics Valley, passive products are established (passive products do not require driving sources, such as cardiovascular stent, such as cardiovascular stenting, such as cardiovascular stenting, such as cardiovascular brackets, such as cardiovascular brackets , Surgery Knife, Disposable Inerades, etc.) and source products (need to use electrical, gas and other drivers, such as various medical electrical equipment, including ultrasound, laser, high frequency/radio frequency, etc.) and production bases. , And have been put into use.

Tang Weikun proudly introduced that the company has carried out clinical trials of innovative drugs in 38 countries and regions around the world, and actively promoted the research and development of products in the fields of intensive and anti -infective infection. STC3141, the world's first innovative medicine, has been promoted in five countries around the world. It has been promoted in five countries around the world. Seven clinical approvals are approved in indications, and the international multi -center clinical clinical is also being comprehensively promoted. "These innovative products will be the company's new profit growth point in the future." What made Tang Weikun proudly was that as of May this year, more than 130 projects under the research projects were under research, including nearly 50 projects in the world, more than 20 items in the world. Clinical trials are approved overseas, especially the company's cardiovascular and cerebrovascular accurate intervention platforms, and 10 equipment products have been reserved. In addition, covering 6 cardiovascular and cerebrovascular diseases. In terms of scientific research capabilities, Yuanda Pharmaceutical has 5 R & D centers under Wuhan Optics Valley, Australia, Belgium, Boston, and San Diego, USA. 14 pharmaceutical members distributed in 7 countries overseas can carry out research and development innovation in 35 countries around the world. Work.

Wonderful quotation

The doctor is sincere, the doctor is benevolent. Centers to meet the needs of patients, in line with market development, and adhere to technological innovation as the driving force. Yuanda Medicine has been committed to developing good products, meeting unsatisfactory clinical needs, and helping patients get rid of disease trouble.

In the 83 -year development process of Yuanda Medicine, we have always practiced the development strategy of the long -term value management of the governor and adhering to the development concept of "comprehensive advantages, innovation leadership and global expansion". Today, Yuanda Pharmaceutical has developed into a scientific and technological innovation -oriented international pharmaceutical company dedicated to becoming a doctor and patients. In the future, we will, as always, centered on the needs of patients, accelerate the introduction of various innovative products, and allow more domestic patients to use innovative drugs synchronizing with international good treatment effects.

Source: Hubei Daily All Media Reporter Hu Man Li Yan

- END -